Background: Non-small cell lung cancer (NSCLC) exhibits low survival rates. Although immune checkpoint inhibitors (ICIs) have become first-line treatment for NSCLC. their limited response to ICI monotherapy has led to exploration of combination treatments. However. https://www.opheliasmuse.com/